Compare SoFi Technologies Inc (SOFI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs BIO-TECHNE Corp — how do they compare? SoFi Technologies Inc trades at $15.75 (market cap $20.23B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: SoFi Technologies Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SoFi Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SoFi Technologies Inc for 60 Days and BIO-TECHNE Corp for 63 Days on average.
| SOFI | TECH | |
|---|---|---|
Market Cap | $20.23B | $11.37B |
Volume | 32,692,405 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $32.21 | $72.61 |
52-Week Low | $15.15 | $43.31 |
Typical Hold Time | 60 Days | 63 Days |
Enterprise Value | $20.37B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOFI stock trades at $15.61, down 0.95% on the day, with a bearish technical signal and mixed sentiment. Revenue grew to $3.61B in 2025, with net income of $481.32M, but cash flow from operations remains negative. The company has beaten EPS estimates in recent quarters, with Q3 2026 results expected soon. Analyst consensus is a Buy with a $21.58 price target, though technical indicators suggest near-term pressure.
Outlook: SOFI offers growth potential with strong revenue expansion and a diversified fintech platform, but faces risks from negative operating cash flow, high valuation multiples, and sensitivity to interest rates. The stock's current discount to analyst targets may present opportunity, but investors should weigh execution risks and macroeconomic headwinds.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
